Calos M P
Department of Genetics, Stanford University School of Medicine, CA 94305, USA.
Trends Genet. 1996 Nov;12(11):463-6. doi: 10.1016/0168-9525(96)40049-x.
Persistence of DNA vectors in target cells is advantageous in most applications of gene therapy. Particularly when target cells are undergoing proliferation, vector longevity will depend on either the integration of the vector into the chromosomes or the ability of the vector to replicate and be retained extrachromosomally. Vectors that efficiently integrate in a nonrandom fashion are currently unavailable, and those that can replicate extrachromosomally provide a major alternative strategy. Several classes of such vectors are under development, carrying mechanisms for prolonging DNA retention in mammalian nuclei that extend vector lifetime in non-proliferating cells as well. The vectors utilize either chromosomal or viral elements to mediate replication and retention, and have a large size capacity for insertion of genes of interest. I discuss the state of the art for these vectors, including the assets and limitations of their future use in gene therapy.
在基因治疗的大多数应用中,DNA载体在靶细胞中的持久性是有利的。特别是当靶细胞正在增殖时,载体的寿命将取决于载体整合到染色体中,或者取决于载体复制并在染色体外保留的能力。目前还没有能够以非随机方式有效整合的载体,而那些能够在染色体外复制的载体提供了一种主要的替代策略。几类这样的载体正在开发中,它们携带延长DNA在哺乳动物细胞核中保留时间的机制,这也能延长载体在非增殖细胞中的寿命。这些载体利用染色体或病毒元件来介导复制和保留,并且具有较大的容量来插入感兴趣的基因。我讨论了这些载体的现有技术水平,包括它们未来在基因治疗中应用的优点和局限性。